Filing Flows › Comparisons › RVMD vs BCRX
Revolution Medicines vs Biocryst Pharmaceuticals: RVMD and BCRX compared
Revolution Medicines is the larger company: $198M of revenue in its latest quarter (Q3 2026) against $180M for Biocryst Pharmaceuticals (Q3 2026). Biocryst Pharmaceuticals is more profitable, with an operating margin of 29.6% against -188.9%.
Where the money goes: RVMD and BCRX
Revolution Medicines (RVMD) · Q3 2026
Revolution Medicines, Q3 2026: revenue $198M, operating margin -188.9%, net loss $407M, operating cash flow −$416M. The chart follows the revenue to costs, profit and cash.
Biocryst Pharmaceuticals (BCRX) · Q3 2026
Biocryst Pharmaceuticals, Q3 2026: revenue $180M (+13% year over year), operating margin 29.6%, net earnings $37.9M, operating cash flow $33.0M. The chart follows the revenue to costs, profit and cash.
| Revolution Medicines (RVMD) | Biocryst Pharmaceuticals (BCRX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $198M | $180M |
| Revenue growth, Y/Y | — | +13% |
| Operating margin | -188.9% | 29.6% |
| Net earnings | −$407M | $37.9M |
| Net margin | -206.2% | 21.0% |
| Operating cash flow | −$416M | $33.0M |
| Free cash flow | — | $32.8M |
Where the revenue comes from
Biocryst Pharmaceuticals
- Product: $172M (96%)
- License and other revenues: $8.0M (4%)
Questions
Which is bigger, Revolution Medicines or Biocryst Pharmaceuticals?
Revolution Medicines is the larger company: $198M of revenue in its latest quarter (Q3 2026) against $180M for Biocryst Pharmaceuticals (Q3 2026).
Is Revolution Medicines or Biocryst Pharmaceuticals growing faster?
Biocryst Pharmaceuticals is more profitable, with an operating margin of 29.6% against -188.9%.
More: Revolution Medicines earnings · how Revolution Medicines makes money · Biocryst Pharmaceuticals earnings · how Biocryst Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.